Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474)

Journal of Nutritional Biochemistry

Volumn 26, Issue 1, 2015, Pages 16-23

  Mason, Julie K ^a   Fu, Minghua ^a   Chen, Jianmin ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Drug diet interaction; Flaxseed oil; HER2; Trastuzumab; Linolenic acid

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID; LINSEED OIL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; PROTEIN KINASE B; TRASTUZUMAB; TUMOR MARKER; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL MAMMARY NEOPLASM; FATTY ACID ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; LINSEED OIL; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84926250731     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.08.001     Document Type: Article

References (40)

1. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006, 8:215.
2. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
3. Baselga J., Phase I.I. Study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
4. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
5. Boon H.S., Olatunde F., Zick S.M. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 2007, 7:4.
6. Boucher B.A., Cotterchio M., Curca I.A., Kreiger N., Harris S.A., Kirsh V.A., et al. Intake of phytoestrogen foods and supplements among women recently diagnosed with breast cancer in Ontario. Can Nutr Cancer 2012, 64:695-703.
7. Cunnane S.C. Dietary sources and metabolism of α-linolenic acid. Flaxseed in Human Nutrition 2003, 63-91. AOCS Press, Champaign, IL. 2nd ed. L.U. Thompson, S.C. Cunnane (Eds.).
8. Thompson L.U., Boucher B.A., Liu Z., Cotterchio M., Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 2006, 54:184-201.
9. Thompson L.U., Chen J.M., Li T., Strasser-Weippl K., Goss P.E. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 2005, 11:3828-3835.
10. Chen J., Power K.A., Mann J., Cheng A., Thompson L.U. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways. Nutr Cancer 2007, 58:162-170.
11. Chen J., Power K.A., Mann J., Cheng A., Thompson L.U. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood) 2007, 232:1071-1080.
12. Truan J.S., Chen J.M., Thompson L.U. Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen. Mol Nutr Food Res 2010, 54:1414-1421.
13. Saggar J.K., Chen J., Corey P., Thompson L.U. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways. Mol Nutr Food Res 2010, 54:415-425.
14. Saggar J.K., Chen J., Corey P., Thompson L.U. The effect of secoisolariciresinol diglucoside and flaxseed oil, alone and in combination, on MCF-7 tumor growth and signaling pathways. Nutr Cancer 2010, 62:533-542.
15. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26:60-70.
16. Menendez J.A., Ropero S., Mehmi I., Atlas E., Colomer R., Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 2004, 24:1369-1383.
17. Ghosh-Choudhury T., Mandal C.C., Woodruff K., St Clair P., Fernandes G., Choudhury G.G., et al. Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat 2009, 118:213-228.
18. Mason J.K., Fu M.H., Chen J., Yu Z., Thompson L.U. Dietary flaxseed-trastuzumab interactive effects on the growth of HER2-overexpressing human breast tumors (BT-474). Nutr Cancer 2013, 65:451-459.
19. Mason J.K., Chen J., Thompson L.U. Flaxseed oil-trastuzumab interaction in breast cancer. Food Chem Toxicol 2010, 48:2223-2226.
20. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58:2825-2831.
21. Menendez J.A., Vazquez-Martin A., Ropero S., Colomer R., Lupu R. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". Clin Transl Oncol 2006, 8:812-820.
22. Horwitz W.A.I. Official methods of analysis of AOAC International 2002, AOAC International, Gaithersburg, MD.
23. Reeves P.G., Nielsen F.H., Fahey G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123:1939-1951.
24. Guide to the Care and Use of Experimental Animals 1984, Canadian Council on Animal Care.
25. Rosenberg C.R., Pasternack B.S., Shore R.E., Koenig K.L., Toniolo P.G. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994, 140:518-525.
26. Fu M.H., Maher A.C., Hamadeh M.J., Ye C., Tarnopolsky M.A. Exercise, sex, menstrual cycle phase, and 17beta-estradiol influence metabolism-related genes in human skeletal muscle. Physiol Genomics 2009, 40:34-47.
27. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
28. O'Malley F.P., Parkes R., Latta E., Tjan S., Zadro T., Mueller R., et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001, 115:504-511.
29. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
30. Chen C.T., Liu Z., Ouellet M., Calon F., Bazinet R.P. Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids 2009, 80:157-163.
31. Wiggins A.K., Mason J.K., Thompson L.U. Beneficial influence of diets enriched with flaxseed and flaxseed oil on cancer. Cancer Chemoprevention and Treatment by Diet Therapy 2013, 55-90. Springer Science+Business Media Dordrecht, Dordrecht, The Netherlands. W.C.S. Cho (Ed.).
32. Wang C.X., Koay D.C., Edwards A., Lu Z., Mor G., Ocal I.T., et al. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat 2005, 92:251-263.
33. Vu T., Claret F.X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2012, 2:62.
34. MacLennan M.B., Clarke S.E., Perez K., Wood G.A., Muller W.J., Kang J.X., et al. Mammary tumor development is directly inhibited by lifelong n-3 polyunsaturated fatty acids. J Nutr Biochem 2013, 24:388-395.
35. Corsetto P.A., Cremona A., Montorfano G., Jovenitti I.E., Orsini F., Arosio P., et al. Chemical-physical changes in cell membrane microdomains of breast cancer cells after omega-3 PUFA incorporation. Cell Biochem Biophys 2012, 64:45-59.
36. Schley P.D., Brindley D.N., Field C.J. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 2007, 137:548-553.
37. Lee E.J., Yun U.J., Koo K.H., Sung J.Y., Shim J., Ye S.K., et al. Down-regulation of lipid raft-associated onco-proteins via cholesterol-dependent lipid raft internalization in docosahexaenoic acid-induced apoptosis. Biochim Biophys Acta 1841, 2014:190-203.
38. deFazio A., Chiew Y.E., Sini R.L., Janes P.W., Sutherland R.L. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000, 87:487-498.
39. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919.
40. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.